Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2024-01-16 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement from the London Stock Exchange, indicated by the 'RNS Number' header and the concluding boilerplate text mentioning RNS and the FCA. The content itself is a 'TR-1: Standard form for notification of major holdings' concerning Barclays PLC crossing a threshold of voting rights in Dechra Pharmaceuticals PLC. This type of mandatory disclosure regarding changes in significant share ownership (crossing thresholds) directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2024-01-16 English
Scheme of Arrangement becomes Effective
M&A Activity Classification · 98% confidence The document is an official announcement dated January 16, 2024, concerning a 'RECOMMENDED CASH ACQUISITION' of Dechra Pharmaceuticals PLC by Freya Bidco Limited. It explicitly states that the 'Scheme of Arrangement becomes Effective' and details the subsequent suspension and cancellation of listing/trading of Dechra Shares. It also mentions the consideration and settlement process, and notes board changes. The presence of 'RNS Number : 8602Z' and the extensive legal/regulatory disclaimers regarding the Takeover Code, FCA, and London Stock Exchange strongly indicate this is a formal regulatory disclosure related to a major corporate action (takeover/merger). This fits the description of M&A Activity (TAR) or a general Regulatory Filing (RNS). Since the core subject is the completion of a takeover/acquisition, TAR is the most specific fit. It is not a short announcement of a report publication (RPA) as it contains substantive details about the transaction completion, not just a link to an attached report.
2024-01-16 English
Holding(s) in Company
Regulatory Filings Classification · 98% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding boilerplate text mentioning RNS and the London Stock Exchange. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in voting rights and financial instruments held by a major shareholder (Bank of America Corporation). This type of mandatory disclosure regarding significant share ownership changes falls under regulatory reporting. Since 'Major Shareholding Notification' (MRQ) is a specific category, and this document is a standard regulatory form notification, MRQ is the most precise fit. It is not a general regulatory filing (RNS) because a more specific category exists.
2024-01-16 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Dechra Pharmaceuticals PLC, dated 15 January 2024. The content explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs)'. This involves directors (Ian Page, Paul Sandland) acquiring shares under various incentive plans (LTIP, SAYE, Deferred Bonus Plan). This type of filing, reporting personal share transactions by directors/executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it is published via RNS, the specific content mandates the DIRS classification over the general RNS fallback.
2024-01-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from the London Stock Exchange. The title is 'TR-1: Standard form for notification of major holdings', and the content details the acquisition/disposal of voting rights by UBS Group AG, crossing a threshold. This type of mandatory disclosure regarding changes in significant share ownership directly corresponds to the Major Shareholding Notification category.
2024-01-15 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a Public Opening Position Disclosure/Dealing Disclosure by a person with interests representing 1% or more in relevant securities during a takeover situation. This type of mandatory disclosure regarding interests in securities during a takeover bid is highly specific and relates to insider/significant shareholder activity concerning a potential M&A event. While it involves share dealings, its primary context is the Takeover Code, which is distinct from standard Director's Dealing (DIRS) or general Capital/Financing (CAP). Given the options, this filing is most closely related to the regulatory requirements surrounding a takeover bid, which falls under the scope of M&A Activity (TAR) or, more generally, a specific regulatory disclosure. However, since the document details personal/entity holdings and dealings related to a specific offeror/offeree under the Takeover Code, it is a specialized form of insider/significant shareholder disclosure related to a potential takeover. Since 'TAR' (M&A Activity) covers merger proposals or takeover bids, and this form is directly triggered by such an event, it is the most appropriate classification, although 'DIRS' (Director's Dealing) is related to insider activity, this is specifically takeover-related disclosure. Given the context of the Takeover Code, it is a mandatory disclosure related to the M&A process.
2024-01-15 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.